Posts by: Steve Bryson PhD

Steve Bryson PhD

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.

November 11, 2020November 11, 2020

Esbriet or Ofev Reduce Inflammatory and Oxidative Stress Markers in IPF, Small Study Shows

News

Esbriet (pirfenidone) or Ofev (nintedanib) treatment in adults with idiopathic pulmonary fibrosis (IPF) led to changes in blood markers reflecting reduced systemic inflammation and oxidative stress after 24 weeks ... Read more

November 6, 2020November 6, 2020

Anticoagulant DOACs Better Than Warfarin in IPF, Analysis Finds

News

Use of the well-known anticoagulant therapy warfarin in people with idiopathic pulmonary fibrosis (IPF) is associated with reduced transplant-free survival, but direct oral anticoagulants (DOACs) are not, a study ... Read more

November 4, 2020November 4, 2020

Ofev, Esbriet Use Seen to Lengthen Life for IPF Patients With ‘Mild’ Disease

News

A real-world analysis found that idiopathic pulmonary fibrosis (IPF) patients with preserved lung function benefitted from treatment with Ofev (nintedanib) and Esbriet (pirfenidone) over three years. Despite untreated patients entering ... Read more

September 9, 2020September 9, 2020

Inhaled Nintedanib May Reduce Side Effects of Oral Formulation, Rat Study Shows

News

An inhaled formulation of nintedanib — the active ingredient in Ofev — demonstrated enhanced antifibrotic effects after short-duration doses compared to oral formulations given at a higher dose in ... Read more

September 8, 2020September 10, 2020

Ofev Effective in IPF Patients With Poor Lung Function, Real-world Study Finds

News

Ofev (nintedanib) is safe and effective for adults with idiopathic pulmonary fibrosis (IPF) with poorer lung function, a small real-world analysis has found. Age and lung function predicted the ... Read more

September 2, 2020September 2, 2020

Specific Gene Mutation Linked to PF and Emphysema in Japanese Patients, Study Suggests

News

Japanese people diagnosed with both pulmonary fibrosis (PF) and emphysema appear to carry a single genetic mutation that contributes to the development of both conditions, a study reports. This ... Read more

August 21, 2020August 21, 2020

Adelmidrol Effectively Treated Pulmonary Fibrosis in Mice, Study Finds

News

Adelmidrol therapy reduced markers for inflammation and oxidative stress, as well as tissue damage and collagen deposits, in the lungs of mice with pulmonary fibrosis (PF), a study has found. ... Read more

July 31, 2020July 31, 2020

Blocking 15-PGDH Enzyme Seen to Ease Inflammation, Fibrosis in Mouse Model

News

Blocking an enzyme — called 15-PGDH — in a mouse model of pulmonary fibrosis (PF) limited early-stage inflammation and the development of fibrosis in the lungs, aiding the animals’ survival, ... Read more

July 7, 2020July 7, 2020

Low Testosterone Levels Linked to Chromosome Damage in Men With IPF

News

The protective tips of chromosomes, called telomeres, are shorter in men with idiopathic pulmonary fibrosis (IPF) than age-matched peers, and these changes seem to be linked to lower blood ... Read more

July 6, 2020July 6, 2020

IPF Hospitalizations, Mortality Rate Seen to Drop in US from 2006-16

News

Rates of hospitalization and in-hospital mortality dropped significantly for people with idiopathic pulmonary fibrosis (IPF) in the U.S. between 2006 and 2016, and hospitalizations were most common in colder ... Read more